KILITCH
FAIRLY_VALUEDKilitch Drugs (India) Limited
Pharma · NSE
↓ 13.9% vs fair value
52W Low
₹117
+56.0% from low
52W High
₹250
-26.8% from high
Valuation Gauge
Current Price
₹183
Fair Value
₹161
Fair Value Analysis
₹161
Based on earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 14th percentile vs sector peers. | ROCE improving (latest 12.8%) — capital allocation becoming more efficient. | Growth capped at 10.8% (ROE 9.4%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable. | COVID-resilient: PAT dropped from ₹4Cr (FY2019) to ₹1Cr (FY2020) during COVID but has fully recovered.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Solid Fundamentals
Profitability
ROE of 9.4% is below the Pharma sector benchmark of 18%
Debt & Leverage
D/E ratio of 0.3x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 20.7x trades at a 51% discount to Pharma sector median (42x) — attractively valued
Cash Flow
Negative FCF of ₹-29 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of 53.6% is well above the Pharma sector average of 15.3% — strong growth
Dividend
No dividend — typical for growth-stage companies
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-4.2%
Free cash flow / market cap
Revenue Growth (YoY)
-4.2%
Year-on-year revenue change
Profit Growth (YoY)
-23.2%
Year-on-year PAT change
Operating Cash Flow
₹18 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹7.5
P/E Ratio
20.7x
P/B Ratio
2x
ROE
9.4%
ROCE
17.3%
Debt / Equity
0.32x
Beta
0.14
Div Yield
—
FCF (Cr)
₹-29 Cr
Revenue (Cr)
₹197 Cr
EPS Growth 5Y
53.6%
Mkt Cap (Cr)
₹537 Cr
52W High
₹250
52W Low
₹117.3
Book Value/Share
₹78.1
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹207 Cr | ₹29 Cr | 14.0% | ₹25 Cr | ₹7.45 |
| 2025-03-31 | ₹198 Cr | ₹32 Cr | 16.0% | ₹25 Cr | ₹7.63 |
| 2024-03-31 | ₹154 Cr | ₹24 Cr | 16.0% | ₹14 Cr | ₹4.17 |
| 2023-03-31 | ₹140 Cr | ₹18 Cr | 13.0% | ₹8 Cr | ₹3.08 |
| 2022-03-31 | ₹114 Cr | ₹10 Cr | 9.0% | ₹6 Cr | ₹2.17 |
| 2021-03-31 | ₹68 Cr | ₹5 Cr | 8.0% | ₹4 Cr | ₹1.09 |
| 2020-03-31 | ₹53 Cr | ₹0 Cr | 1.0% | ₹1 Cr | ₹0.25 |
| 2019-03-31 | ₹82 Cr | ₹7 Cr | 9.0% | ₹4 Cr | ₹1.15 |
| 2018-03-31 | ₹51 Cr | ₹6 Cr | 11.0% | ₹5 Cr | ₹1.72 |
| 2017-03-31 | ₹27 Cr | ₹-1 Cr | -2.0% | ₹-9 Cr | ₹-3.09 |
| 2016-03-31 | ₹21 Cr | ₹-4 Cr | -19.0% | ₹-11 Cr | ₹-3.89 |
| 2015-03-31 | ₹19 Cr | ₹-2 Cr | -9.0% | ₹0 Cr | ₹-0.10 |
| 2012-03-31 | ₹108 Cr | ₹13 Cr | 12.0% | ₹76 Cr | ₹26.50 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86.4 | ₹469.7 | +81.6% | 7.7 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹118.2 | ₹237.8 | +50.3% | 26.8 | 5.2% | FAIRLY_VALUED |
Bal Pharma Limited | ₹82.3 | ₹147.5 | +44.2% | 15.7 | 12.6% | FAIRLY_VALUED |
Lincoln Pharmaceuticals Limited | ₹732.1 | ₹1,131.6 | +35.3% | 14.7 | 13.1% | FAIRLY_VALUED |
Zydus Lifesciences | ₹1,038.6 | ₹1,502.2 | +30.9% | 20.6 | 19.9% | UNDERVALUED |
Lupin | ₹2,270.7 | ₹3,112 | +27.0% | 19.5 | 26.9% | UNDERVALUED |
Natco Pharma | ₹1,170 | ₹1,571.3 | +25.5% | 13.8 | 18.0% | UNDERVALUED |
Sudeep Pharma Limited | ₹675 | ₹739.2 | +8.7% | 43.7 | 21.4% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant